Clinical TrialJun 29, 2026, 08:46 AM
Artelo Biosciences ART26.12 Phase 1 Study Shows Favorable Safety
AI Summary
Artelo Biosciences announced positive results from the first-in-human Phase 1 clinical study of ART26.12, its selective FABP5 inhibitor, at the ICRS 2026 Annual Symposium. The study showed ART26.12 was well-tolerated with favorable safety and predictable pharmacokinetics. Additionally, new AI-aided biomarker research identified potential indicators of target engagement and pharmacological activity, strengthening confidence in ART26.12's potential as a non-opioid therapy.
Key Highlights
- ART26.12 Phase 1 study demonstrated favorable safety and tolerability across all dose levels.
- ART26.12 exhibited predictable, linear, dose-dependent pharmacokinetics.
- Plasma concentrations of ART26.12 exceeded projected therapeutic levels based on preclinical studies.
- AI-aided analysis identified treatment-related changes in lipid metabolism, inflammation, and other biological pathways.
- New biomarker data aims to establish pharmacodynamic biomarkers for future clinical development and optimal dosing.
Price Impact
More from ARTL